The reduction in price target by Piper Sandler, despite maintaining an Overweight rating, could lead to short-term negative sentiment among investors. This adjustment reflects a recalibration of expectations, possibly due to underlying challenges or revised market outlooks that could impact Cytek Biosciences' stock price negatively in the short term.